 |
|
Statin Use, Bone Mineral Density, and Fracture Risk
Geelong Osteoporosis Study
Julie A. Pasco, PhD;
Mark A. Kotowicz, MBBS, FRACP;
Margaret J. Henry, PhD;
Kerrie M. Sanders, MNutr, PhD;
Geoffrey C. Nicholson, MBBS, PhD, FRACP, FRCP
Arch Intern Med. 2002;162:537-540.
Background Recent data suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins) decrease fracture risk and increase bone mineral density
(BMD).
Methods This cross-sectional study is set in southeastern Australia. We evaluated
the association between statin use, fracture risk, and BMD in 1375 women (573
with incident fractures and 802 without incident fracture, all drawn from
the same community). Fractures were identified radiologically. Medication
use and lifestyle factors were documented by questionnaire.
Results Unadjusted odds ratio for fracture associated with statin use was 0.40
(95% confidence interval [CI], 0.23-0.71). Adjusting for BMD at the femoral
neck, spine, and whole body increased the odds ratio to 0.45 (95% CI, 0.25-0.80),
0.42 (95% CI, 0.24-0.75), and 0.43 (95% CI, 0.24-0.78), respectively. Adjusting
for age, weight, concurrent medications, and lifestyle factors had no substantial
effect on the odds ratio for fracture. Statin use was associated with a 3%
greater adjusted BMD at the femoral neck (P = .08),
and BMD tended to be greater at the spine and whole body but did not achieve
statistical significance.
Conclusion The substantial 60% reduction in fracture risk associated with statin
use is greater than would be expected from increases in BMD alone.
From the Department of Clinical and Biomedical Sciences–Barwon
Health, The University of Melbourne, Geelong Hospital, Geelong, Australia.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2002;162(5):615.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial
Bone et al.
J. Clin. Endocrinol. Metab. 2007;92:4671-4677.
ABSTRACT
| FULL TEXT
Determinants of the Differences in LDL-Cholesterol After Initiation of Statin Treatment
Caspard et al.
The Annals of Pharmacotherapy 2006;40:21-26.
ABSTRACT
| FULL TEXT
Plasma Low-Density Lipoprotein Cholesterol and Bone Mass Densitometry in Postmenopausal Women
Poli et al.
Obstet Gynecol 2003;102:922-926.
ABSTRACT
| FULL TEXT
Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study
LaCroix et al.
ANN INTERN MED 2003;139:97-104.
ABSTRACT
| FULL TEXT
Statin Use Is Associated with Improved Function and Survival of Lung Allografts
Johnson et al.
Am. J. Respir. Crit. Care Med. 2003;167:1271-1278.
ABSTRACT
| FULL TEXT
Tackling ischaemic heart disease in rheumatoid arthritis
Kitas and Erb
Rheumatology (Oxford) 2003;42:607-613.
FULL TEXT
Falls and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Pasco et al.
Arch Intern Med 2002;162:2381-2381.
FULL TEXT
Statin Use and Fracture Risk
Seeger et al.
Arch Intern Med 2002;162:2379-2380.
FULL TEXT
|
